News

NewAmsterdam Pharma Set for Key Presentations and Events in September

NewAmsterdam Pharma Set for Key Presentations and Events in September

NewAmsterdam Pharma's Upcoming Events and Presentations

NAARDEN and MIAMI — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), a leader in biopharmaceutical innovations, is gearing up for a series of significant events in the coming weeks. This late-stage clinical biopharmaceutical firm is dedicated to developing oral, non-statin medications aimed at patients facing cardiovascular disease (CVD) risks due to elevated low-density lipoprotein cholesterol (LDL-C). Unfortunately, current treatment options often fall short for these individuals. To address this, NewAmsterdam will share pivotal findings on their investigational treatments at key industry gatherings.

European Society of Cardiology Congress

This year, NewAmsterdam will present at the esteemed European Society of Cardiology Congress (ESC), scheduled from August 29 to September 1. This Congress serves as a prominent platform for cardiology professionals worldwide, offering insights into cutting-edge research and treatments. NewAmsterdam will highlight pooled safety and efficacy data from the Phase 3 BROADWAY and BROOKLYN trials.

Presentation Details

One of the key presentations will be on the efficacy of obicetrapib across various lipid-lowering therapies based on the Broadway and Brooklyn randomized trials. Dr. Kausik Ray will present this enlightening session titled "Changing Face of Lipid-Lowering Therapy" on August 29 at 10:10 AM CEST. Additionally, Dr. Stephen Nicholls will discuss the impact of obicetrapib on cardiovascular events during the "Late-Breaking Clinical Science" session on September 1 at 9:00 AM CEST.

Participation in Investor Conferences

Aside from the ESC, NewAmsterdam will also engage actively in several crucial investor conferences during the same time frame. One highlighted event is Citi's 2025 Biopharma Back to School Summit on September 3, where CEO Michael Davidson and CFO Ian Somaiya will participate in a fireside chat at 2:30 PM ET in Boston.

Other Notable Conferences

NewAmsterdam will continue its conference schedule with the Cantor Global Healthcare Conference on September 4, presenting again with Dr. Davidson and Mr. Somaiya at 2:45 PM ET in New York. Finally, the company will conclude their participation in this series with the Wells Fargo Healthcare Conference on September 5, showcasing insights from CFO Ian Somaiya at 10:15 AM ET in Boston.

Webcast Availability

For those unable to attend, live webcasts of these presentations will be accessible via the investor relations section of the NewAmsterdam Pharma website. Following these live events, recorded sessions will also be made available for later viewing, ensuring that stakeholders stay informed of the latest developments.

About NewAmsterdam Pharma

NewAmsterdam Pharma (Nasdaq: NAMS) is committed to enhancing patient outcomes for metabolic diseases, particularly in populations with unmet medical needs. The company is focused on ensuring patients have access to safe and effective therapies that significantly lower LDL levels while being well-tolerated. NewAmsterdam is striving to broaden the therapeutic options by utilizing obicetrapib—a once-daily CETP inhibitor—to enhance LDL-C reduction, especially in patients already on statin therapies who are often underserved by existing treatments.

Company Contact Information

Matthew Philippe
P: 1-917-882-7512
Email: matthew.philippe@newamsterdampharma.com

Frequently Asked Questions

What is the purpose of NewAmsterdam Pharma's upcoming presentations?

The presentations aim to showcase new data from their clinical trials on LDL-C treatments, which could significantly impact cardiology practices.

When and where will the European Society of Cardiology Congress take place?

The Congress is set for August 29 to September 1 in Madrid, serving as a significant platform for health professionals in cardiology.

Who will represent NewAmsterdam Pharma at the investor conferences?

CEO Michael Davidson and CFO Ian Somaiya will be key presenters at multiple investor events, engaging with industry stakeholders.

Will the presentations be available for later viewing?

Yes, live webcasts will be provided and recordings will be accessible for those who cannot attend the live sessions.

What is NewAmsterdam Pharma's core mission?

The company aims to innovate safe and effective treatments for metabolic diseases, particularly for patients at risk of cardiovascular complications.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

CELSET Unveils SOLTOX: Expanding in Global Markets

Updated Category News Views 73

New Contender in the Global Botulinum Toxin Arena Launching a fresh player onto the international stage, CELSET INC. from Seoul throws down with SOLTOX, their own botulinum toxin Type A brand. This ain't your run-of-the-mill roll-out; it's another notch for Korean biotech trying to snag a piece of global market action. A Look at SOLTOX's Technical Makeup We’re talking...

Continue Reading
Banco Macro S.A. Plans $160B Share Buyback Initiative

Updated Category News Views 24

Tapping into Share Buybacks in a Tumultuous Market Out of nowhere, Banco Macro S.A. has decided to whip up a share buyback program, a lifeline for their current market value. Let me tell you, the market's more volatile than a caffeinated squirrel these days, hitting the financial scenery harder than a hammer on a glass table. So, Banco Macro's taken a deep breath and...

Continue Reading
Enertech's New Moves Aim to Make Geothermal Mainstream

Updated Category News Views 74

Breaking Through Financial Barriers in Geothermal Energy Finally, we're seeing some real movement in the geothermal heat pump sector. The longtime hurdles that kept ground-sourced heating and cooling tech at arm's length from the everyday homeowner are starting to tumble, thanks to Enertech Global's latest initiatives. Enertech's Double Deal: A New Lease on Geothermal...

Continue Reading
Agrochemicals: Combining Tradition and Innovation

Updated Category News Views 69

The Evolving World of Agrochemicals You know, the agrochemical market isn't just about fertilizers and pesticides anymore. It's evolving into a high-stakes game of innovation, resistance management, and cutting-edge tech. This whole sector's forecast to explode to a whopping US$ 387.7 billion by 2031. That's no small potatoes. Driving Forces: Pests, Drones, and Regulatory...

Continue Reading
Insurify's AI Gateway: A New Era in Insurance Shopping

Updated Category News Views 66

Insurify's Game-Changing AI Agent Gateway In the insurance world, Insurify's latest move feels like a bull charging through a ticker tape parade. This Cambridge-based pioneer unveiled its AI Agent Gateway, aiming to put consumers back in the driver's seat. By connecting digital assistant agents to its platform, Insurify's making insurance shopping a bit less like pulling...

Continue Reading
Royce Micro-Cap Trust: Navigating Small-Cap Waves

Updated Category News Views 42

Folks, if there's ever been a niche in this labyrinth of stocks, it’s the micro-cap territory. Royce Micro-Cap Trust (NYSE: RMT) is hefting the torch for smaller companies up to a billion in market cap. But is it leading the charge or getting steamrolled by market bear crawls? Understanding the Numbers Time to get dirty with some numbers, because for Royce Micro-Cap...

Continue Reading
Pave and Levels.fyi Unite: Revolutionize Pay Decisions

Updated Category News Views 99

Diving straight into the heart of it, here's a move in the business world that's all but marking its territory on the compensation landscape. Pave, already a big player in agentic compensation management, is shaking hands with Levels.fyi, a platform prized for its real-deal compensation data detailed down to the company, level, location, and skill. These folks are...

Continue Reading
Innovative Trial Targets Drug Resistance in Lung Cancer

Updated Category News Views 68

The Battle Against Drug Resistance Heats Up Folks, we're in a never-ending fight here against one of the toughest adversaries out there: lung cancer. And lemme tell ya, when drugs show resistance, it's like trying to punch a ghost. But there’s a fresh wind blowing, as Dr. Bobak Parang steps up to the plate with a $620K grant aimed squarely at tackling drug resistance in...

Continue Reading
Photocure's Q3 2026: Revenue Plateau and CFO Shakeup

Updated Category News Views 111

The Bladder Cancer Scene: Steady as She Goes Sometimes, you look at numbers and find tranquility, like staring into still waters. That's the scene over at Photocure ASA with their latest Q3 results. Clocking in with revenues of NOK 134.2 million from their Hexvix®/Cysview® products, they're barely flinching from last year's NOK 134.1 million. Is it a victory or a...

Continue Reading
Royce Small-Cap Trust Shows Resilience Amid Volatility

Updated Category News Views 95

A Closer Look at Royce's Latest Moves Royce Small-Cap Trust (NYSE: RVT), the venerable old timer in the small-cap fund world, has been trucking along the market's bumpy byways since forever ago. With over 50 years of small- and micro-cap investment experience under its belt, you'd think it might have seen everything by now. But in the volatile world of small caps,...

Continue Reading

Top 5 Most Recently Viewed Articles

Workplace Safety Sector Expected to Reach $38.55 Billion by 2030

Updated Category News Views 138

Introduction to Workplace Safety Market Growth The global Workplace Safety Market is on a remarkable trajectory, expected to expand from USD 19.64 billion in 2025 to USD 38.55 billion by 2030. This signifies an impressive compound annual growth rate (CAGR) of 14.4%. With businesses increasingly prioritizing safety and compliance, this growth reflects not just numbers but...

Continue Reading
YinzCam Launches Innovative Basketball App in the UAE Market

Updated Category News Views 136

YinzCam Expands to the UAE with New Mobile Application PITTSBURGH and DUBAI, UAE — YinzCam, an industry leader in mobile app development, is making waves by launching its first mobile app in the United Arab Emirates. This application, created in partnership with Dubai Basketball, represents a significant milestone as the franchise enters the EuroLeague and Adriatic...

Continue Reading
Jet Linx Unveils Free In-Flight WiFi for Jet Card Members

Updated Category News Views 149

Jet Linx Enhances Connectivity for Jet Card Members Jet Linx, a leading provider in the private aviation sector, has recently made a significant enhancement to its Jet Card offerings by introducing complimentary in-flight WiFi on Super Midsize and Heavy Jet flights. This new feature marks a noteworthy commitment to improving the travel experience for its Jet Card Members....

Continue Reading
Urgent Message From Lawyer About Spain's Tax Compliance Issues

Updated Category News Views 247

Urgent Call to Address Spain's Tax Practices International lawyer Robert Amsterdam stands ready to take action regarding alarming tax practices in Spain that could have profound implications for U.S. investors and businesses. His firm, Amsterdam & Partners LLP, is set to unveil a critical white paper titled "Hacienda vs. The People," which delves into the troubling...

Continue Reading
Growth Potential and Strategic Shifts at Duckhorn Portfolio

Updated Category News Views 173

Strategic Overview of Duckhorn Portfolio The Duckhorn Portfolio, Inc. (NYSE: NAPA), a distinguished name in the luxury wine sector, has garnered major attention recently owing to its acquisition by Butterfly Equity. While this exciting development unfolds, the company is also managing various market challenges that necessitate a thorough exploration of NAPA's current...

Continue Reading